Why the study?
Does torcetrapib/atorvastatin reduce atherosclerotic progression compared to atorvastatin alone in patients with heterozygous familial hypercholesterolemia or mixed hyperlipidemia?
Does torcetrapib/atorvastatin reduce atherosclerotic progression compared to atorvastatin alone in patients with heterozygous familial hypercholesterolemia or mixed hyperlipidemia?
Answers are grounded in this paper and cite their sources.
The RADIANCE studies are designed to evaluate whether adding torcetrapib to atorvastatin slows the progression of atherosclerosis compared to atorvastatin alone in patients with hypercholesterolemia or mixed hyperlipidemia.
OBJECTIVE: The RADIANCE studies were designed to assess the effects of torcetrapib/atorvastatin (T/A) compared with atorvastatin alone on slowing atherosclerotic progression in patients with heterozygous familial hypercholesterolemia (RADIANCE 1) or mixed hyperlipidemia (RADIANCE 2), as measured by change in carotid intima-media thickness (CIMT). RESEARCH DESIGN AND METHODS: RADIANCE 1 and 2 were randomized, double-blind, controlled trials with a duration of 2 years. In both studies, eligible subjects began treatment with atorvastatin during a run-in period and were titrated to target LDL-C levels defined by NCEP ATP III guidelines. Subjects then proceeded to a double-blind randomized treatment period where they received one of two regimens: (i) fixed combination T/A (torcetrapib dose, 60 mg), or (ii) atorvastatin alone. In both regimens, the dose of atorvastatin was established during the run-in period (20-80 mg, RADIANCE 1; 10-80 mg RADIANCE 2). B-mode ultrasonography was performed in duplicate at baseline and at end of study, and every 6 months in between. MAIN OUTCOME MEASURES: The primary efficacy measure in both studies was the annualized rate of change in maximum CIMT of 12 pre-defined carotid segments. Further outcome measures included lipid and safety assessments. CURRENT STATUS: The number of subjects randomized was 904 in RADIANCE 1 and 752 in RADIANCE 2. Results are anticipated in 2007.
No takes yet. Share an insight, caveat, or question.
Kastelein et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: